Healthy normal volunteers, Mild cognitive impairment (MCI), Alzheimer disease (AD)
Conditions
Interventions
None listed
Sponsors
Study Group on diagnosis of Alzheimer disease by amyloid imaging using [11C]BF-227
1)Department of Geriatrics and Gerontology, Tohoku University School of medicine 2)Cyclotron and Radioisotope Center, Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Criteria for Normal volunteers: Normal Volunteers are examined by FDG-PET, [11C]BF-227-PET, MRI and psychological tests. Male and female volunteers aged more than 35 years old are recruited for this study. They should understand the purpose and rationale of this study. 2)Criteria for Alzheimer disease: Alzheimer patients diagnosed as a probable AD according to NINCDS-ADRDA are enrolled. MMSE (Mini-mental state examination) is over 18, and apparent cognitive dysfunction is present in the patients. Informed consents are obtained from patients family and possibly from patients themselves. 3)Criteria for Mild Cognitive Impairment 1.Amnestic MCI. 2.No apparent neurological and psychiatric disorders. 3.There are no neurological symptoms. 4.There are no psychiatric symptoms. 5.The patients do not show dementia.
Exclusion criteria
Exclusion criteria: 1)The past and present history of alcoholism. 2)The past and present history of epilepsy 3)Education period is less than 6 years. 4)There are no persons who can give any information on patients symptoms. 5)Diabetic patients treated with insulin 6)Patients treated with antidepressants, antipsychotics, and long-term sedative-hypnotics. 7)Severe complication including malignancy, heart failure, hepatic dysfunction, renal dysfunction, endocrine disorders, etc. 8)Other patients and volunteers that investigators and medical doctors need to exclude.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The molecular PET imaging using [11C]BF-227. The [11C]BF-227-PET is evaluated by cortical SUV ratios to cerebellum as a reference among healthy volunteers, mild cognitive impairment, and Alzheimer patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| The comparison of FDG-PET, MRI, psychological cognitive tests, and [11C]BF-227-PET among healthy volunteers, mild cognitive impairment, and Alzheimer patients. The [11C]BF-227-PET is evaluated by cortical SUV ratios to cerebellum as a reference | — |
Countries
Japan
Contacts
Public ContactDr. Nobuyuki Okamura
Tohoku University Graduate School of Medicine Department of Pharmacology
Outcome results
None listed